Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Methylphenidate in terminal depression

¹Department of Psychological Medicine, Christchurch School of Medicine, New Zealand.

Journal of Pain and Symptom Management

|October 14, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early constipation predicts faster dementia onset in Parkinson's disease.

NPJ Parkinson's disease·2021

Same author

Untangling chronic pain and post-concussion symptoms: the significance of depression.

Brain injury·2018

Same author

Medium-term prognosis of an incident cohort of parkinsonian patients compared to controls.

Parkinsonism & related disorders·2016

Same author

Motor complications in an incident Parkinson's disease cohort.

European journal of neurology·2015

Same author

Euthanasia and physician-assisted dying: editorial comment and reply to the Waikato GP survey findings by Dr Havill.

The New Zealand medical journal·2015

Same author

Impaired eye movements in post-concussion syndrome indicate suboptimal brain function beyond the influence of depression, malingering or intellectual ability.

Brain : a journal of neurology·2009

Same journal

Coping with Breathlessness in Individuals with Lung Diseases: A Systematic Review and Meta-Synthesis.

Journal of pain and symptom management·2026

Same journal

Growing the Next Generation of Hospice and Palliative Medicine Researchers.

Journal of pain and symptom management·2026

Same journal

Topical Amitriptyline, Ketamine, and Lidocaine Cream for Neuropathic Pain Control in Pediatric Oncology Patients.

Journal of pain and symptom management·2026

Same journal

Perceived Stigma, Psychological Distress, and Symptom Burden in Decompensated Cirrhosis.

Journal of pain and symptom management·2026

Same journal

Routine Urine Drug Screening in Palliative Care - A Call for Evidence Before Implementation.

Journal of pain and symptom management·2026

Same journal

Why We Should Rarely Override Surrogates.

Journal of pain and symptom management·2026

See all related articles

Methylphenidate showed a therapeutic response in 46% of hospice patients with major depressive disorder. However, significant improvement was rare in patients nearing death, suggesting higher psychostimulant doses may be needed.

Area of Science:

Geriatric Medicine
Psychiatry
Palliative Care

Background:

Major depressive disorder is common in hospice patients.
Effective management of depression in terminally ill patients is challenging.
Psychostimulants are a potential treatment option.

Purpose of the Study:

To evaluate the efficacy of methylphenidate for major depressive disorder in hospice inpatients.
To determine response rates in relation to prognosis.

Main Methods:

A trial of methylphenidate was administered to 26 hospice inpatients.
Mean daily dosage was 17.7 mg.
Response was assessed therapeutically and significantly.

Main Results:

Related Experiment Videos

A therapeutic response was achieved in 46% of patients.
A significant response was observed in only 7% of patients who died within 6 weeks.
Lower response rates were noted in patients with a poor prognosis.

Conclusions:

Methylphenidate may offer therapeutic benefits for depression in some hospice patients.
Higher doses of psychostimulants might be necessary for terminally ill patients in their final weeks.
"Vital exhaustion" could explain poor treatment response in advanced malignancy.